https://de.marketscreener.com/kurs/aktie/TAKEDA-PHARMACEUTICAL-COM-6491073/news/Takeda-Pharmaceutical-Phase-3-Studie-mit-NINLARO-Ixazomib-als-Erhaltungstherapie-erreicht-prim-26912117/?utm_source=telegram&utm_medium=social&utm_campaign=share